Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives
09 mai 2024 07h30 HE
|
Attovia Therapeutics, Inc.
-- Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform -- Financing led by Goldman Sachs...
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.
Medigene to Present at Upcoming Conferences
07 mai 2024 09h00 HE
|
Medigene AG
Planegg/Martinsried, May 7, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
02 mai 2024 04h30 HE
|
Medigene AG
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
02 mai 2024 02h30 HE
|
Medigene AG
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease
01 mai 2024 06h55 HE
|
Janssen Cilag International NV
Media contact:Sophie DaneauSdaneau@its.jnj.com+33 6 3178 8798Investor contact:Raychel Kruperinvestor-relations@its.jnj.com For European and UK medical and trade media only For immediate...
EAACI Congress 2024: นวัตกรรมและความก้าวหน้าในการรักษาโรคภูมิแพ้
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
ในระหว่างการประชุมจะมีการนำเสนอเซสชันทางวิทยาศาสตร์มากกว่า 150 ครั้ง โดยมุ่งเน้นที่ความก้าวหน้าทางวิทยาศาสตร์สิ่งแวดล้อม โรคภูมิแพ้อาหาร นวัตกรรมในการใช้ภูมิคุ้มกันบำบัดและโรคภูมิแพ้ในเด็ก และอื่นๆ...
Congreso EAACI 2024: Innovación y Avances en el Tratamiento de Alergias
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
Durante el congreso se presentarán más de 150 sesiones científicas centradas en los avances en ciencia medioambiental, alergias alimentarias, innovaciones en inmunoterapia o alergias pediátricas,...
2024년도 EAACI 학술대회: 알레르기 치료의 혁신과 발전
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
학술대회 일환으로 환경 과학, 식품 알레르기, 면역 치료 혁신, 소아 알레르기 등의 주제에 초점 맞춘 150개 이상의 과학 세션 열릴 예정최대 규모의 알레르기 및 면역학 학술대회에서 다뤄질 정밀 의학, AI, 면역 치료, 면역 조절제5월 31일부터 6월 3일까지 스페인 발렌시아에서 개최 스페인 발렌시아, April 30, 2024 (GLOBE...
קונגרס EAACI 2024: חדשנות והתקדמות בטיפול באלרגיה
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
במהלך הקונגרס יוצגו למעלה מ-150 מושבים מדעיים, שיתמקדו בין היתר בהתקדמות במדעי הסביבה, אלרגיות למזון, חידושים באימונותרפיה ואלרגיות ילדים.רפואה מדויקת, בינה מלאכותית, אימונותרפיה ומודולטורים...